trial · primary record
TSRA-196
Alpha-1 Antitrypsin Deficiency (AATD)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 72 |
| Primary completion | 2029-03 |
| Primary endpoint | Part 1 (Dose Escalation): Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) |
| Registry ID | NCT07227207 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:55.610Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07227207
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.